Discontinuation report EVISTA
| Report ID | 257316 |
| Drug Identification Number | 02239028 |
| Brand name | EVISTA |
| Common or Proper name | raloxifene hydrochloride tablet |
| Company Name | ELI LILLY CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | RALOXIFENE HYDROCHLORIDE |
| Strength(s) | 60MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Carton containing 28 tablets in blister packaging |
| ATC code | G03XC |
| ATC description | OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2026-01-30 |
| Actual discontinuation date | |
| Remaining supply date | 2026-01-30 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Anticipated remaining supply date may be impacted based on any changes in demand. |
| Company comments | For any questions, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
| Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-05-14 | French | Compare |
| v1 | 2025-05-14 | English | Compare |
Showing 1 to 2 of 2